The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls

British Journal of Haematology

Volumn 152, Issue 5, 2011, Pages 561-569

  Hill, Brian T ^a   Rybicki, Lisa ^b   Bolwell, Brian J ^a   Smith, Stephen ^a   Dean, Robert ^a   Kalaycio, Matt ^a   Pohlman, Brad ^a   Tench, Shawnda ^a   Sobecks, Ronald ^a   Andresen, Steven ^a   Copelan, Edward ^a   Sweetenham, John ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma; Late effects; Treatment related mortality

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RESPIRATORY FAILURE; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIDEMIOLOGIC METHODS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79951523047     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08549.x     Document Type: Article

References (27)

1. Armenian, S.H., Sun, C.L., Francisco, L., Steinberger, J., Kurian, S., Wong, F.L., Sharp, J., Sposto, R., Forman, S.J. & Bhatia, S. (2008) Late congestive heart failure after hematopoietic cell transplantation. Journal of Clinical Oncology, 26, 5537-5543.
2. van Besien, K., Tabocoff, J., Rodriguez, M., Andersson, B., Mehra, R., Przepiorka, D., Dimopoulos, M., Giralt, S., Suki, S., Khouri, I. et al (1995) High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplantation, 15, 549-555.
3. Bhatia, S., Robison, L.L., Francisco, L., Carter, A., Liu, Y., Grant, M., Baker, K.S., Fung, H., Gurney, J.G., McGlave, P.B., Nademanee, A., Ramsay, N.K., Stein, A., Weisdorf, D.J. & Forman, S.J. (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood, 105, 4215-4222.
4. Bolwell, B., Kalaycio, M., Sobecks, R., Andresen, S., McBee, M., Kuczkowski, L., Rybicki, L. & Pohlman, B. (2002) Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplantation, 29, 673-679.
5. Brown, J.R., Yeckes, H., Friedberg, J.W., Neuberg, D., Kim, H., Nadler, L.M. & Freedman, A.S. (2005) Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 2208-2214.
6. Copelan, E.A., Penza, S.L., Pohlman, B., Avalos, B.R., Goormastic, M., Andresen, S.W., Kalaycio, M., Bechtel, T.P., Scholl, M.D., Elder, P.J., Ezzone, S.A., O'Donnell, L.C., Tighe, M.B., Risley, G.L., Young, D.C. & Bolwell, B.J. (2000) Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation, 25, 1243-1248.
7. Damon, L., Damon, L.E., Gaensler, K., Kaplan, L., Martin, III, T., Rubenstein, J. & Linker, C. (2008) Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 42, 649-657.
8. Dean, R.M., Pohlman, B., Sweetenham, J.W., Sobecks, R.M., Kalaycio, M.E., Smith, S.D., Copelan, E.A., Andresen, S., Rybicki, L.A., Curtis, J. & Bolwell, B.J. (2009) Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. British Journal of Haematology, 148, 226-234.
9. Fenske, T.S., Hari, P.N., Carreras, J., Zhang, M.J., Kamble, R.T., Bolwell, B.J., Cairo, M.S., Champlin, R.E., Chen, Y.B., Freytes, C.O., Gale, R.P., Hale, G.A., Ilhan, O., Khoury, H.J., Lister, J., Maharaj, D., Marks, D.I., Munker, R., Pecora, A.L., Rowlings, P.A., Shea, T.C., Stiff, P., Wiernik, P.H., Winter, J.N., Rizzo, J.D., van Besien, K., Lazarus, H.M. & Vose, J.M. (2009) Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biology of Blood and Marrow Transplantation, 15, 1455-1464.
10. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117-4126.
11. Finkelstein, D.M., Muzikansky, A. & Schoenfeld, D.A. (2003) Comparing survival of a sample to that of a standard population. Journal of the National Cancer Institute, 95, 1434-1439.
12. Fu, K., Weisenburger, D.D., Choi, W.W., Perry, K.D., Smith, L.M., Shi, X., Hans, C.P., Greiner, T.C., Bierman, P.J., Bociek, R.G., Armitage, J.O., Chan, W.C. & Vose, J.M. (2008a) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Journal of Clinical Oncology, 26, 4587-4594.
13. Fu, P., van Heeckeren, W.J., Wadhwa, P.D., Bajor, D.J., Creger, R.J., Xu, Z., Cooper, B.W., Laughlin, M.J., Gerson, S.L., Koc, O.N. & Lazarus, H.M. (2008b) Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation. Contemporary Clinical Trials, 29, 157-164.
14. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf- Peeters, C., Falini, B. & Gatter, K.C. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
15. Hernandez-Ilizaliturri, F.J. & Czuczman, M.S. (2009) Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park), 23, 546-553.
16. Hoyert, D.L., Kochanek, K.D. & Murphy, S.L. (1999) The National Center for Health Statistics, National Vital Statistics Reports volume 47, No. 19, June 30 1999, pages 3-5.
17. Jantunen, E., Itala, M., Lehtinen, T., Kuittinen, O., Koivunen, E., Leppa, S., Juvonen, E., Koistinen, P., Wiklund, T., Nousiainen, T., Remes, K. & Volin, L. (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. European Journal of Haematology, 76, 245-250.
18. Kalaycio, M., Pohlman, B., Kuczkowski, E., Rybicki, L., Andresen, S., Sobecks, R. & Bolwell, B. (2006a) High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant. Clinical Transplantation, 20, 783-787.
19. Kalaycio, M., Rybicki, L., Pohlman, B., Sobecks, R., Andresen, S., Kuczkowski, E. & Bolwell, B. (2006b) Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. Journal of Clinical Oncology, 24, 3604-3610.
20. Majhail, N.S., Bajorunaite, R., Lazarus, H.M., Wang, Z., Klein, J.P., Zhang, M.J. & Rizzo, J.D. (2009) Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. British Journal of Haematology, 147, 129-139.
21. Pedersen-Bjergaard, J., Andersen, M.K. & Christiansen, D.H. (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood, 95, 3273-3279.
22. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y. & Harousseau, J.L. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540-1545.
23. Rodriguez, J., Caballero, M.D., Gutierrez, A., Solano, C., Arranz, R., Lahuerta, J.J., Sierra, J., Gandarillas, M., Perez-Simon, J.A., Zuazu, J., Lopez-Guillermo, A., Sureda, A., Carreras, E., Garcia-Larana, J., Marin, J., Garcia, J.C., Fernandez De Sevilla, A., Rifon, J., Varela, R., Jarque, I., Albo, C., Leon, A., SanMiguel, J. & Conde, E. (2004) Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Annals of Oncology, 15, 1504-1509.
24. Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. & Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857-1861.
25. Shipp, M., Harrington, D.P. & Anderson, J.A. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987-994.
26. Vellenga, E., van Putten, W.L., van 't Veer, M.B., Zijlstra, J.M., Fibbe, W.E., van Oers, M.H., Verdonck, L.F., Wijermans, P.W., van Imhoff, G.W., Lugtenburg, P.J. & Huijgens, P.C. (2008) Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood, 111, 537-543.
27. Weaver, C.H., Schwartzberg, L.S., Hainsworth, J., Greco, F.A., Li, W., Buckner, C.D. & West, W.H. (1997) Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplantation, 19, 671-678.